biologic

Enbrel

etanercept

Loss of exclusivitySeptember 2016projected — 12-year biologic exclusivity estimate
CompanyImmunex Corporation

Drug detail

Brand nameEnbrel
Active ingredientetanercept
Strength50MG/ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalSeptember 2004
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Enbrel patent cliff — loss of exclusivity September 2016 | CliffBio